Editorial: Advances in pneumococcal vaccines: The 13-valent pneumococcal conjugate vaccine received market authorization in Europe

Expert Review of Vaccines

Volumn 9, Issue 3, 2010, Pages 229-236

  Reinert, Ralf R ^a   Paradiso, Peter ^a   Fritzell, Bernard ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; C REACTIVE PROTEIN; CD32 ANTIGEN; DIPHTHERIA TOXOID; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G; INTERLEUKIN 10; INTERLEUKIN 8; MACROLIDE; MANNOSE BINDING LECTIN; PENICILLIN G; PNEUMOCOCCUS POLYSACCHARIDE; PNEUMOCOCCUS VACCINE; PREVENAR 13; UNCLASSIFIED DRUG; 13 VALENT PNEUMOCOCCAL VACCINE; 13-VALENT PNEUMOCOCCAL VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC SENSITIVITY; ANTIBODY TITER; AUSTRALIA; BACTEREMIA; BACTERIAL COLONIZATION; BLEEDING; CANADA; CHILE; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG SAFETY; EDITORIAL; EMPYEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; EUROPE; FRANCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; GERMANY; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOGENICITY; INFECTION PREVENTION; ITALY; MENINGITIS; MORBIDITY; MORTALITY; NASOPHARYNX; NEUTROPHIL; OTITIS MEDIA; PATHOGENESIS; PNEUMOCOCCAL INFECTION; PNEUMONIA; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL; SEROTYPE; SOUTH AFRICA; SPAIN; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; UNITED KINGDOM; UNITED STATES; VACCINATION; WORLD HEALTH ORGANIZATION; DRUG APPROVAL; IMMUNIZATION; IMMUNOLOGY;

CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EUROPE; HUMANS; IMMUNIZATION SCHEDULE; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES;

EID: 77949439406     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.10.6     Document Type: Editorial

References (56)

1. EMEA. Committee for Medicinal Products for Human Use (CHMP). Prevenar 13: Summary of Product Characteristics (2009).
2. WHO. Pneumococcal conjugate vaccine for childhood immunization - WHO position paper. Wkly Epidemiol. Rec. 82(12), 93-104 (2007).
3. O'Brien KL, Wolfson LJ, Watt JP et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374(9693), 893-902 (2009).
4. Centers for Disease Control and Prevention. Vaccine preventable deaths and the global immunization vision and strategy, 2006-2015. MMWR Morb. Mortal. Wkly Rep. 55, 511-515 (2006).
5. Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity, and treatment. Clin. Infect. Dis. 14(4), 801-807 (1992).
6. Dinleyici EC, Yargic ZA. Pneumococcal conjugated vaccines: impact of PCV-7 and new achievements in the postvaccine era. Expert Rev. Vaccines 7(9), 1367-1394 (2008).
7. Rose M, Zielen S. Impact of infant immunization programs with pneumococcal conjugate vaccine in Europe. Expert Rev. Vaccines 8(10), 1351-1364 (2009).
8. Centers for Disease Control and Prevention. Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - eight states, 1998-2005. MMWR Morb. Mortal. Wkly Rep. 57(6), 144-148 (2008).
9. Kellner JD, Vanderkooi OG, MacDonald J, Church DL, Tyrrell GJ, Scheifele DW. Changing epidemiology of invasive pneumococcal disease in Canada, 1998-2007: update from the Calgary-area Streptococcus pneumoniae research (CASPER) study. Clin. Infect. Dis. 49(2), 205-212 (2009).
10. Vestrheim DF, Lovoll O, Aaberge IS et al. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway. Vaccine 26(26), 3277-3281 (2008).
11. Rückinger S, van der Linden M, Reinert RR, von Kries R, Burckhardt F, Siedler A. Reduction in the incidence of invasive pneumococcal disease after general vaccination with 7-valent pneumococcal conjugate vaccine in Germany. Vaccine 27(31), 4136-4141 (2009).
12. Centers for Disease Control and Prevention. Direct and indirect effects of routine vaccination of children with 7-valent pneumococcal conjugate vaccine on incidence of invasive pneumococcal disease - United States, 1998-2003. MMWR Morb. Mortal. Wkly Rep. 54(36), 893-897 (2005).
13. Ray GT, Whitney CG, Fireman BH, Ciuryla V, Black SB. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatr. Infect. Dis. J. 25(6), 494-501 (2006).
14. Grijalva CG, Nuorti JP, Arbogast PG, Martin SW, Edwards KM, Griffin MR. Decline in pneumonia admissions after routine childhood immunisation with pneumococcal conjugate vaccine in the USA: a time-series analysis. Lancet 369(9568), 1179-1186 (2007).
15. Grijalva CG, Poehling KA, Nuorti JP et al. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States. Pediatrics 118(3), 865-873 (2006).
16. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics 121(2), 253-260 (2008).
17. Bechini A, Boccalini S, Bonanni P. Immunization with the 7-valent conjugate pneumococcal vaccine: impact evaluation, continuing surveillance and future perspectives. Vaccine 27(25-26), 3285-3290 (2009).
18. Feavers I, Knezevic I, Powell M, Griffiths E. Challenges in the evaluation and licensing of new pneumococcal vaccines, 7-8 July 2008, Ottawa, Canada. Vaccine 27(28), 3681-3688 (2009).
19. Dinleyici EC, Yargic ZA. Current knowledge regarding the investigational 13-valent pneumococcal conjugate vaccine. Expert Rev. Vaccines 8(8), 977-986 (2009).
20. Destefano F, Pfeifer D, Nohynek H. Safety profile of pneumococcal conjugate vaccines: systematic review of pre- and post-licensure data. Bull. World Health Organ. 86(5), 373-380 (2008).
21. Hausdorff WP, Dagan R, Beckers F, Schuerman L. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27(52), 7257-7269 (2009).
22. Isaacman DJ, McIntosh ED, Reinert RR. Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines. Int. J. Infect. Dis. (2009) (Epub ahead of print).
23. Rodgers GL, Arguedas A, Cohen R, Dagan R. Global serotype distribution among Streptococcus pneumoniae isolates causing otitis media in children: potential implications for pneumococcal conjugate vaccines. Vaccine 27(29), 3802-3810 (2009).
24. Moore MR, Gertz RE Jr, Woodbury RL et al. Population snapshot of emergent Streptococcus pneumoniae serotype 19A in the United States, 2005. J. Infect. Dis. 197(7), 1016-1027 (2008).
25. O'Brien KL. Pneumoccal regional serotype distribution for pneumoccal AMC TPP. AMC TPP Codebook. GAVI's PneumoADIP, MD, USA (2008).
26. Hausdorff WP. The roles of pneumococcal serotypes 1 and 5 in paediatric invasive disease. Vaccine 25(13), 2406-2412 (2007).
27. Fletcher M, Leeming J, Cartwright K, Finn A. Childhood empyema: limited potential impact of 7-valent pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 25(6), 559-560 (2006).
28. Byington CL, Korgenski K, Daly J, Ampofo K, Pavia A, Mason EO. Impact of the pneumococcal conjugate vaccine on pneumococcal parapneumonic empyema. Pediatr. Infect. Dis. J. 25(3), 250-254 (2006).
29. Reinert RR. The antimicrobial resistance profile of Streptococcus pneumoniae. Clin. Microbiol. Infect. 15(Suppl. 3), 7-11 (2009).
30. Fenoll A, Granizo JJ, Aguilar L et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J. Clin. Microbiol. 47(4), 1012-1020 (2009).
31. Hicks LA, Harrison LH, Flannery B et al. Incidence of pneumococcal disease due to non-pneumococcal conjugate vaccine (PCV7) serotypes in the United States during the era of widespread PCV7 vaccination, 1998-2004. J. Infect. Dis. 196(9), 1346-1354 (2007).
32. Ardanuy C, Rolo D, Fenoll A, Tarrago D, Calatayud L, Linares J. Emergence of a multidrug-resistant clone (ST320) among invasive serotype 19A pneumococci in Spain. J. Antimicrob. Chemother. 64(3), 507-510 (2009).
33. Dagan R, Givon-Lavi N, Leibovitz E, Greenberg D, Porat N. Introduction and proliferation of multidrug-resistant Streptococcus pneumoniae serotype 19A clones that cause acute otitis media in an unvaccinated population. J. Infect. Dis. 199(6), 776-785 (2009).
34. Hwa Choi E, Hee Kim S, Wook Eun B et al. Streptococcus pneumoniae serotype 19A in children, South Korea. Emerg. Infect. Dis. 14(2), 275-281 (2008).
35. Jacobs MR, Good CE, Bajaksouzian S, Windau AR. Emergence of Streptococcus pneumoniae serotypes 19A, 6C, and 22F and serogroup 15 in Cleveland, Ohio, in relation to introduction of the protein-conjugated pneumococcal vaccine. Clin. Infect. Dis. 47(11), 1388-1395 (2008).
36. Pai R, Moore MR, Pilishvili T, Gertz RE, Whitney CG, Beall B. Postvaccine genetic structure of Streptococcus pneumoniae serotype 19A from children in the United States. J. Infect. Dis. 192(11), 1988-1995 (2005).
37. Pelton SI, Huot H, Finkelstein JA et al. Emergence of 19A as virulent and multidrug resistant Pneumococcus in Massachusetts following universal immunization of infants with pneumococcal conjugate vaccine. Pediatr. Infect. Dis. J. 26(6), 468-472 (2007).
38. Porat N, Soley C, Marengolciene MM et al. An international serotype 3 clone causing pediatric noninvasive infections in Israel, Costa Rica, and Lithuania. Pediatr. Infect. Dis. J. 27(8), 709-712 (2008).
39. Bender JM, Ampofo K, Korgenski K et al. Pneumococcal necrotizing pneumonia in Utah: does serotype matter? Clin. Infect. Dis. 46(9), 1346-1352 (2008).
40. Carvalho Mda G, Pimenta FC, Gertz RE Jr et al. PCR-based quantitation and clonal diversity of the current prevalent invasive serogroup 6 pneumococcal serotype, 6C, in the United States in 1999 and 2006 to 2007. J. Clin. Microbiol. 47(3), 554-559 (2009).
41. Cohen R, Levy C, Bonnet E et al. Dynamic of pneumococcal nasopharyngeal carriage in children with acute otitis media following PCV7 introduction in France. Vaccine DOI:10.1016/j.vaccine.2009.05.037 (2009) (Epub ahead of print).
42. Park S, Nahm M. Functional cross-reactivity within S. pneumoniae serogroup 6 elicited by pneumococcal conjugate polysaccharide vaccines). Presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, CA, USA, 12-15 September 2009.
43. Facklam R, Beall B, Efstratiou A et al. Emm typing and validation of provisional M types for group A streptococci. Emerg. Infect. Dis. 5(2), 247-253. (1999).
44. Bratcher PE, Kim KH, Kang JH, Hong JY, Nahm MH. Identification of natural pneumococcal isolates expressing serotype 6D by genetic, biochemical, and serological characterization. Microbiology 156, 555-560 (2009).
45. Jin P, Kong F, Xiao M et al. First report of putative Streptococcus pneumoniae serotype 6D among nasopharyngeal isolates from Fijian children. J. Infect. Dis. 200(9), 1375-1380 (2009).
46. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect. Dis. 8(12), 785-795 (2008).
47. Weinberger DM, Trzcinski K, Lu YJ et al. Pneumococcal capsular polysaccharide structure predicts serotype prevalence. PLoS Pathog. 5(6), e1000476 (2009).
48. Hanage WP, Fraser C, Tang J, Connor TR, Corander J. Hyper-recombination, diversity, and antibiotic resistance in pneumococcus. Science 324(5933), 1454-1457 (2009).
49. Bogaert D, Weinberger D, Thompson C, Lipsitch M, Malley R. Impaired innate and adaptive immunity to Streptococcus pneumoniae and its effect on colonization in an infant mouse model. Infect. Immun. 77(4), 1613-1622 (2009).
50. Payton A, Payne D, Mankhambo LA et al. Nitric oxide synthase 2A (NOS2A) polymorphisms are not associated with invasive pneumococcal disease. BMC Med. Genet. 10, 28 (2009).
51. Chapman SJ, Khor CC, Vannberg FO et al. IkB genetic polymorphisms and invasive pneumococcal disease. Am. J. Respir. Crit. Care Med. 176(2), 181-187 (2007).
52. Chapman SJ, Khor CC, Vannberg FO et al. NFKBIZ polymorphisms and susceptibility to pneumococcal disease in European and African populations. Genes Immun. DOI:10.1038/gene.2009.76 (2009) (Epub ahead of print).
53. Chapman SJ, Vannberg FO, Khor CC et al. Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease. Mol. Immunol. 44(12), 3267-3270 (2007).
54. Khor CC, Chapman SJ, Vannberg FO et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat. Genet. 39(4), 523-528 (2007).
55. Moens L, Verhaegen J, Pierik M et al. Toll-like receptor 2 and Toll-like receptor 4 polymorphisms in invasive pneumococcal disease. Microbes Infect. 9(1), 15-20 (2007).
56. Moens L, Van Hoeyveld E, Verhaegen J, De Boeck K, Peetermans WE, Bossuyt X. Fcg-receptor IIA genotype and invasive pneumococcal infection. Clin. Immunol. 118(1), 20-23 (2006).